ONCOSIL MEDICAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.005 AUD | 0.00% |
|
0.00% | -44.44% |
| 02:48am | Oncosil Medical Enters Distribution Agreement with Abdulla Fouad Group for Saudi Arabia | MT |
| May. 02 | OncoSil Medical Raises AU$5.3 Million under Entitlement Offer | MT |
| Sales 2022 | 1.06M 705K | Sales 2023 | 1.47M 973K | Capitalization | 23.71M 15.71M |
|---|---|---|---|---|---|
| Net income 2022 | -10M -6.63M | Net income 2023 | -11M -7.29M | EV / Sales 2022 | 27 x |
| Net cash position 2022 | 10.98M 7.27M | Net cash position 2023 | 9.22M 6.11M | EV / Sales 2023 | 9.87 x |
| P/E ratio 2022 |
-3.02
x | P/E ratio 2023 |
-1.2
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 88.35% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 month | +25.00% | ||
| 3 months | -44.44% | ||
| 6 months | -44.44% | ||
| Current year | -44.44% |
1 week
0.00
0.01
1 month
0.000.01
Current year
0.000.01
1 year
0.000.02
3 years
0.000.08
5 years
0.000.22
10 years
0.000.28
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Christian Cin
DFI | Director of Finance/CFO | - | 23-05-31 |
Jon Bell
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Douglas Cubbin
CHM | Chairman | - | 23-08-06 |
| Director/Board Member | - | 23-07-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 0.005 | 0.00% | 1 890 999 |
| 24-05-22 | 0.005 | 0.00% | 787,233 |
| 24-05-21 | 0.005 | 0.00% | 273,005 |
| 24-05-20 | 0.005 | 0.00% | 1,426,510 |
| 24-05-17 | 0.005 | 0.00% | 20,454 |
Delayed Quote Australian S.E., May 23, 2024 at 02:10 am EDT
More quotes
OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.44% | 11.06M | |
| +37.74% | 723B | |
| +34.69% | 595B | |
| -2.07% | 369B | |
| +20.25% | 332B | |
| +2.99% | 282B | |
| +17.13% | 244B | |
| +10.12% | 208B | |
| -4.21% | 205B | |
| +7.43% | 166B |
- Stock Market
- Equities
- OSL Stock
